valsartan (Rx)Brand and Other Names:Diovan

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 40mg
  • 80mg
  • 160mg
  • 320mg
more...

Hypertension

80-160 mg/day PO

Maintenance: 80-320 mg/day PO

Congestive Heart Failure

40 mg PO q12hr

Maintenance: 40-160 mg PO q12hr; not to exceed 320 mg/day

Post-MI Therapy in Left Ventricular Dysfunction

May be initiated >12 hours after myocardial infarction (MI)

20 mg PO q12hr initially, 12 hrs after MI, then increased to 40 mg PO q12hr within 7 days

Maintenance: Titrated to 160 mg PO q12hr as tolerated

Administration

Although food may decrease absorption (by 40%), manufacturer states drug may be administered without regard to meals

Drug may also be given in combination with hydrochlorothiazide (Diovan HCT) or amlodipine (Exforge)

Dosing Modifications

Renal impairment

  • CrCl ≥30 mL/min: No dose adjustment necessary in adults
  • CrCl <30 mL/min: Use with caution in adults; not studied in children

Hepatic impairment

  • Mild to moderate liver impairment: No adjustment necessary; use with caution in liver disease
  • Severe liver impairment: Not studied

Dosing Considerations

Generally, adjust dosage monthly (maximal reduction of BP attained after 4 weeks); adjust more aggressively in high-risk patients and patients with cormorbidities

Dosage Forms & Strengths

tablet

  • 40mg
  • 80mg
  • 160mg
  • 320mg
more...

Hypertension

<6 years: Safety and efficacy not established

≥6 years: 1.3 mg/kg/day PO (not to exceed 40 mg/day); maintenance: 1.3-2.7 mg/kg/day PO (not to exceed 160 mg/day)  

Next

Interactions

Interaction Checker

valsartan and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Dizziness (17%; heart failure)

            Increased blood urea nitrogen (BUN; 17%)

            1-10%

            Hyperkalemia (4-10%)

            Dizziness (2-8%; hypertension)

            Hypotension (1-7%; heart failure)

            Fatigue (3%)

            Viral infection (3%)

            Neutropenia (2%)

            Syncope (>1%)

            Upper abdominal pain (>1%)

            Vertigo (>1%)

            Frequency Not Defined

            Headache

            Cough (rare)

            Postmarketing Reports

            Hypersensitivity: Angioedema (rare)

            Digestive: Elevated liver enzymes, hepatitis (rare)

            Renal: Impaired renal function, renal failure

            Clinical laboratory tests: Hyperkalemia

            Dermatologic: Alopecia, bullous dermatitis

            Blood and lymphatic: Thrombocytopenia (rare)

            Vascular: Vasculitis

            Previous
            Next

            Warnings

            Black Box Warnings

            Discontinue as soon as possible when pregnancy is detected; drug affects renin-angiotensin system, causing oligohydramnios, which may result in fetal injury or death

            Contraindications

            Hypersensitivity

            Do not coadminister with aliskiren in patients with diabetes mellitus

            Cautions

            Use caution in hereditary angioedema, volume depletion, severe congestive heart failure (CHF), hyperkalemia, hepatic or renal impairment, aortic or mitral valve stenosis, surgery, anesthesia

            Discontinue immediately if patient is pregnant; potential risk of congenital abnormalities

            Concomitant use with angiotensin-converting enzyme (ACE) inhibitor and beta blocker is not recommended in CHF patients

            Post-MI treatment: Consider dosage reduction if hypotension or renal dysfunction occurs after MI

            Angioedema, hypotension, hyperkalemia, and renal function deterioration may occur; monitor

            Dosage reduction or discontinuance may be required if hyperkalemia or increased serum creatinine occurs

            Use with caution in renal artery stenosis; avoid in bilateral renal artery stenosis

            Dual blockade of the renin-angiotensin system with angiotensin-receptor blockers (ARBs), ACE inhibitors, or aliskiren is associated with increased risk of hypotension, hyperkalemia, and altered renal function (including acute renal failure) in comparison with monotherapy; closely monitor blood pressure

            Avoid coadministration with aliskiren in patients with renal impairment (ie, GFR <60 mL/min/1.73 m²)

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: D

            Discontinue as soon as pregnancy detected; during the second and third trimesters of pregnancy, resulting oligohydramnios may cause fetal injury (eg, hypotension, neonatal skull hypoplasia, anuria, reversible and irreversible renal failure) and death

            Neonates with a history of in utero exposure: Direct attention toward support of blood pressure and renal perfusion; exchange transfusions or dialysis may be required

            Lactation: No human data; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Blocks binding of angiotensin II to type 1 angiotensin II receptors, causing a lowering in blood pressure; blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II

            Absorption

            Bioavailability: 25%

            Onset: 2 hr

            Duration: 24 hr

            Peak serum time: 2-4 hr

            Peak response: 4-6 hr

            Distribution

            Protein bound: 94-95%

            Vd: 17 L

            Metabolism

            Minimally metabolized in liver

            Metabolites: Valeryl-4-hydroxyvalsartan (inactive)

            Elimination

            Half-life: 6-9 hr

            Renal clearance: 0.62 L/hr

            Total body clearance: 2.2 L/hr

            Excretion: Feces (83%), urine (13%)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.